Skip to main content

Table 2 Outcome matrix

From: Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews

Author

Physical function

Pain

Spinal mobility

Spinal stiffness

Patient’s global assessment

Peripheral joints/entheses

Acute phase reactants

Spine/hip radiograph

Fatigue

SM-ARD trials

 Dougados (1994) [41]

+,+ (DFI)

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

−/−

 Dougados (1999) [42]

+,+ (DFI)

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,+ (CRP)

−/−

 Dougados (2001) [43]

+,+ (BASFI)

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,+ (CRP)

−/−

 Van der Heijde (2005_2) [44]

+,+ (BASFI)

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,+ (BASDAI question 4)

+,+ (CRP)

−/−

 Barkhuizen (2006) [27]

+,+ (BASFI)

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,+ (CRP)

−/−

Physical therapy trials

 Kraag (1990) [45]

+,+ (TADLQ)

+,+ (VAS)

+,+ (Schober)

+,+ (TADLQ)

−/−

 Hidding (1993) [46]

+,+ (DFI 0)

+,+ (VAS)

+,+ (Schober)

+,+ (VAS)

+,+ (VAS)

+,+ (enthesitis index)

−/−

 Helliwell [31]

+,+/− (VAS)

+,+ (Schober)

+,+/− (VAS)

−/−

 Van Tubergen (2001) [47]

+,+ (BASFI)

+,+ (VAS)

+,+ (minutes)

+,+ (VAS)

−/−

 Sweeney (2002) [48]

+,+ (BASFI)

+,+ (SES)

+,+ (BAS-G)

−/−

 Analay (2003) [49]

+,+ (BASFI)

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

−/−

 Codish (2005) [50]

+,+ (BASFI)

+,+ (VAS)

+,+/− (Schober)

−/−

 Fernandez-de-Las-Penas (2005) [51]

+,+ (BASFI)

+,+ (Schober)

−/−

 Lim [30]

+,+ (BASFI)

+,+/− (VAS)

+,+ (FFD)

−/−

 Ince (2006) [52]

+,+ (Schober)

−/−

 Altan (2006) [53]

+,+ (BASFI)

+,+ (VAS)

+,+ (Schober)

+,+ (NRS)

+,+ (NRS)

−/−

DC-ART trials

 Dougados (1986) [54]

+,+ (DFI)

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (enthesitis index)

+,+ (ESR)

−/−

 Feltelius [28]

+,+/− (VAS)

+,+/− (Schober)

+,+ (VAS)

+,+ (VAS)

+,+ (enthesitis index)

+,+ (ESR)

−/−

 Nissila (1988) [55]

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,+ (22-joint count)

+,+ (CRP)

−/−

 Davis (1989) [56]

+,+ (VAS)

+,+ (occiput-to-wall distance)

+,+ (VAS)

+,+ (CRP)

−/−

 Winkler (1989) [57]

+,+ (VAS)

+,+ (Schober)

+,+ (hours)

+,+ (VAS)

+,+ (66-joint count)

+,+ (ESR)

−/−

 Corkill [58]

+,+ (VAS)

+,+ (occiput-to-wall distance)

+,+ (VAS)

+,+ (CRP)

−/−

 Krajnc (1990) [59]

+,+ (Schober)

 

−/−

 Taylor [34]

+,+ (VAS)

+,+ (Schober)

+,+ (VAS)

+,+/− (NRS)

+,+/− (joint count)

+,+ (CRP)

+,+/− SIJ score

 Kirwan [29]

+,− (HAQ)

+,− (VAS)

+,+ (Schober)

+,+/− (VAS)

+,– (VAS)

+,+/− (44-joint count)

−/−

 Clegg (1996) [60]

+,+ (DFI)

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

+,+/− (NRS)

+,+ (44-joint count)

+,+ (CRP)

−/−

 Altan [35]

+,+ (DFI)

+,+ (VAS)

+,− (Schober)

+,+ (minutes)

+,+ (NRS)

+,+ (enthesitis index)

+,+ (CRP)

−/−

 Braun [36]

+,+ (BASFI)

+,+/− (NRS)

+,+ (BASMI)

+,+/− (minutes)

+,+ (NRS)

+,+ (44-joint count)

+,+ (CRP)

−/−

+,+/− (NRS)

 Gorman (2002) [61]

+,+ (BASFI)

+,+/− (VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,+ (66-joint count)

+,+ (CRP)

−/−

 Roychowdhury (2002) [62]

+,+ (BASMI)

+,+ (minutes)

+,+ (CRP)

−/−

 Schmidt (2002) [63]

+,+ (DFI)

+,+ (VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (enthesitis index)

+,+ (CRP)

−/−

 Brandt [37]

+,+ (BASFI)

+,+/− (NRS)

+,+ (BASMI)

+,+/− (NRS)

+,+/− (66-joint count)

+,+/− (CRP)

−/−

+,+/− (NRS)

 Davis (2003) [64]

+,+ (BASFI)

+,+/− (VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,– (68-joint count)

+,+ (CRP)

−/−

 Calin (2004) [65]

+,+ (BASFI 0)

+,+ (VAS)

+,+ (BASMI)

+,+ (minutes)

+,+ (VAS)

+,– (68-joint count)

+,+ (CRP)

−/−

+,+ (VAS)

 Gonzalez-Lopez [38]

+,+ (BASFI)

+,+ (VAS)

+,+ (VAS)

+,+ (VAS)

+,+ (44-joint count)

+,− (ESR)

−/−

 Marzo-Ortega (2005) [66]

+,+ (BASFI)

+,+ (VAS)

+,+ (minutes)

+,+ (enthesitis index)

+,− (ESR)

−/−

 Van der Heijde (2005_1) [44]

+,+ (BASFI)

+,+ (VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (enthesitis Index)

+,+ (CRP)

−/−

 Van der Heijde [32]

+,+ (BASFI)

+,+ (VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (VAS)

+,+ (44-joint count)

+,+ (CRP)

−/−

 Van der Heijde (2006_2) [67]

+,+ (BASFI)

+,+ (VAS)

+,+ (Schober)

+,+ (VAS)

+,+ (VAS)

+,+ (70-joint count)

+,+ (CRP)

−/−

 Lambert (2007) [68]

+,+ (BASFI)

+,+ (VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (VAS)

+,+ (44-joint count)

+,+ (CRP)

−/−

 Inman (2008) [69]

+,+ (BASFI)

+,+ (VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (VAS)

+,+ (CRP)

−/−

+,+ (JESQ)

 Barkham (2010) [70]

+,+ (BASFI)

+,+ (VAS)

−/−

 Inman (2010) [71]

+,+ (BASFI)

+,+ (BASMI)

+,+ (BAS-G)

+,+ (CRP)

−/−

 Braun (2011) [72]

+,+ (BASFI)

+,+ (VAS)

+,+ (BASMI)

+,+/− (VAS)

+,+ (VAS)

+,+ (66-joint count)

+,+ (CRP)

−/−

 Dougados [39]

+,+ (BASFI)

+,+ (VAS)

+,+ (BASMI)

+,− (VAS)

+,+ (CRP)

−/−

 Navarro-Sarabia (2011) [73]

+,+ (BASFI)

+,+ (VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (66-joint count)

+,+ (CRP)

−/−

+,+/− (VAS)

 Hu [40]

+,+ (BASFI)

+,+ (VAS)

+,+ (CRP)

−/−

+,+/− (VAS 0–10)

 Bao (2014) [74]

+,+ (BASFI)

+,+ (VAS)

+,+ (BASMI)

+,+ (CRP)

−/−

+,+ (JESQ)

 Huang (2014) [75]

+,+ (BASFI)

+,+ (VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (VAS)

+,+ (44-joint count)

+,+ (CRP)

−/−

  1. +,+ indicates that outcome was measured and fully reported
  2. +,+/− indicates that outcome was measured and partially reported (e.g., only the P value is given for the comparison)
  3. +,− indicates that outcome was measured but not reported
  4. − indicates that outcome was not measured
  5. Abbreviations: DFI Dougados functional index, VAS visual analogue scale, NRS numeric range scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, BASFI Bath Ankylosing Spondylitis Functional Index, TADLQ Toronto Activity of Daily Living Questionnaire, HAQ Health Assessment Questionnaire, BASRI Bath Ankylosing Spondylitis Radiology Index, SES Stanford Self-Efficacy Scale, BAS-G Bath Ankylosing Spondylitis Global Index, BASDAI Bath Ankylosing Disease Activity Index, SPARCC SpondyloArthritis Research Consortium of Canada, JESQ Jenkins Sleep Evaluation Questionnaire